The short version of LC-MS/MS fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-29. Anything still debated is marked as such rather than presented as settled.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Common supplier description |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water |
| Typical storage | −20 °C, desiccated, dark | For research samples |
| Analytical method | LC-MS/MS | Used for detection and quantification |
| Regulatory status | Prohibited in sport | WADA metabolic modulator class |
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
== History == Hypoglycemia was first recognized in the 19th century. In the 1920s, after the discovery of insulin and its use in the treatment of diabetics, hyperinsulinism was suspected to be a cause of hypoglycemia in nondiabetics. A pioneering description of hyperinsulinism as a cause of hypoglycemia was published by Seale Harris in 1924. The first report of a surgical cure of hypoglycemia by removing an islet cell tumour was in 1929. An insulinoma removed from a woman in Munich provided insulin mRNA that was used in the first human gene cloning experiment. In 1979, Axel Ullrich cloned this gene into E. coli. Most therapeutic insulin used today derives from this woman's tumour.
== Trials == Howard Florey's team at Oxford showed that Penicillium extract killed many kinds of bacteria. Gardner and Orr-Ewing tested it against gonococcus (against which it was most effective), meningococcus, streptococcus, staphylococcus, Bacillus anthracis, actinomyces and tetanus bacterium (Clostridium tetani) and the bacteria that cause gangrene. They observed bacteria attempting to grow in the presence of penicillin, and noted that penicillin was neither an enzyme that broke the bacteria down, nor an antiseptic that killed them; rather, it was a chemical that interfered with the process of cell division. Jennings observed that it had no effect on white blood cells, and would therefore reinforce rather than hinder the body's natural defences against bacteria. She also found that unlike sulphonamides, the first and only effective broad-spectrum antibiotic available at the time, it was not destroyed by pus. Medawar found that it did not affect the growth of tissue cells.
In May 2026, Buc-ee's sued a small North Georgia-based convenience store chain called Teddy's Market for trademark infringement, alleging that its use of a cartoon bear mascot and a name that uses "two-syllable, six-letter possessives ending in an 'eez' sound" would cause customer confusion. Teddy's filed a counterclaim in August, arguing that the stark differences between two companies, such as the sizes of their stores, the marketing used between them, and Teddy's use of BP-branded fuel pumps instead of in-brand pumps, does not constitute infringement, and that Buc-ee's trademark registrations were improperly obtained. During the episode of Last Week Tonight aired on July 26, 2026, John Oliver launched a merch store entitled "Buc-Off." On this site, he launched various made-to-order products featuring a logo parodying the Buc-ee's logo, with the name "Buc-Off" and the beaver replaced with a squirrel character named Mr. Nutterbutter last seen in a segment about frivolous lawsuits. Oliver launched this site in the hopes that Buc-ee's would sue, and fight back in the hopes of avoiding further lawsuits brought on by Buc-ee's towards smaller companies. All proceeds from the merch sales are being donated to Hunger Free America. In July 2026, Buc-ee's sued a small convenience store chain based in Beavercreek, Ohio called Beaver's Mini Mart, alleging that its beaver logo too closely resembled Buc-ee's own "Bucky" beaver mascot.
Sources: en.wikipedia.org
MuscleTech is a brand of dietary supplements, marketed by Iovate Health Sciences Inc., which includes Hydroxycut. It was owned by Canadian company Kerr Holdings which was acquired by Xiwang Foodstuffs Company, a Chinese company, for $584 million in 2016.
== Names == In Middle English, dried and salted cod was called haberdine. Dried cod and the dishes made from it are known by many names around the world, many of them derived from the root bacal-, itself of unknown origin. Explorer John Cabot reported that it was the name used by the inhabitants of Newfoundland. Some of these are: bacalhau (salgado) (Portuguese), bacalao salado (Spanish), bacallau salgado (Galician), bakailao (Basque), bacallà salat i assecat or bacallà salat (Catalan), μπακαλιάρος, bakaliáros (Greek), Klippfisch (German), morue salée (French), baccalà (Italian), bacałà (Venetian), bakalar (Croatian), bakkeljauw (Surinamese Dutch), bakaljaw (Maltese), makayabu (Central and East Africa), Okporoko (Igbo-Nigeria) and kapakala (Finnish). Other names include ráktoguolli/goikeguolli (Sami), klipfisk (Danish) klippfisk/kabeljo (Swedish), stokvis/klipvis (Netherlandish Dutch), saltfiskur [ˈsal̥tˌfɪskʏr̥] (Icelandic), morue (French), bartolitius (Canadian), and saltfish (Anglophone I Caribbean).
The organic compound citrulline is a non-essential α-amino acid. Its name is derived from citrullus, the Latin word for watermelon. Although named and described by gastroenterologists since the late 19th century, it was first isolated from watermelon in 1914 by Japanese researchers Yatarō Koga and Ryō Ōtake, and further codified in 1930. Citrulline has the formula H2NC(O)NH(CH2)3CH(NH2)CO2H. It is a key intermediate in the urea cycle, the pathway by which mammals excrete ammonia by converting it into urea. Citrulline is also produced as a byproduct of the enzymatic production of nitric oxide from the amino acid arginine, catalyzed by nitric oxide synthase.
=== RNA sequences can be edited within cells === Messenger RNA precursors from a wide range of organisms can be edited before being translated into protein. In this process, non-encoded nucleotides may be inserted into specific sites in the RNA, and encoded nucleotides may be removed or replaced. RNA editing was first discovered within the mitochondria of kinetoplastid protozoans, where it has been shown to be extensive. For example, some protein-coding genes encode fewer than 50% of the nucleotides found within the mature, translated mRNA. Other RNA editing events are found in mammals, plants, bacteria and viruses. These latter editing events involve fewer nucleotide modifications, insertions and deletions than the events within kinetoplast DNA, but still have high biological significance for gene expression and its regulation.
Sources: en.wikipedia.org
In 1877, Schumacher adopted the Quaker symbol, the first registered trademark for a breakfast cereal. The acceptance of "horse food" for human consumption encouraged other entrepreneurs to enter the industry. Henry Parsons Crowell started operations in 1882, and John Robert Stuart in 1885. Crowell cut costs by consolidating every step of the processing—grading, cleaning, hulling, cutting, rolling, packaging, and shipping—in one factory operating at Ravenna, Ohio. Stuart operated mills in Chicago and Cedar Rapids, Iowa. Stuart and Crowell combined in 1885 and initiated a price war. After a fire at his mill in Akron, Schumacher joined Stuart and Crowell to form the Consolidated Oatmeal Company. The American Cereal Company (Quaker Oats, but see below) created a cereal made from oats in 1877, manufacturing the product in Akron, Ohio. Separately, in 1888, a trust or holding company combined the nation's seven largest mills into the American Cereal Company using the Quaker Oats brand name. By 1900, technology, entrepreneurship, and the "Man in Quaker Garb"—a symbol of plain honesty and reliability—gave Quaker Oats a national market and annual sales of $10 million (equivalent to $390 million today). Early in the 20th century, the Quaker Oats Company (formed in 1901 to replace the American Cereal Company) ventured into the world market. Schumacher, the innovator; Stuart, the manager and financial leader; and Crowell, the creative merchandiser, advertiser, and promoter, doubled sales every decade. Alexander P.
Electron transfer dissociation takes place in an ion trap mass spectrometer with an electrospray ionization source. The first ETD experiments at the University of Virginia utilized a radio frequency quadrupole linear ion trap (LQT) modified with a chemical ionization (CI) source at the back side of the instrument (see diagram at right). Because a spectrum can be obtained in about 300 milliseconds, liquid chromatography is often coupled with the ETD MS/MS. The disadvantage of using LQT is that the mass resolving power is less than that of other mass spectrometers. Subsequent studies have tried other instrumentation to improve mass resolution. Having a negative CI source at the back of the instrument interfered with the high-resolution analyzer in LQT-Orbitrap and quadrupole time-of-flight (QTOF), so alternate ionization methods for the radical anions have been introduced. In 2006 a group at Purdue University led by Scott McLuckey used a quadrupole/time-of-flight (QqTOF) tandem mass spectrometer with pulsed nano-ESI/atmospheric pressure chemical ionization (APCI) dual ionization source using radical anions of 1,3-dinitrobenzene as the electron donor. Later a lab at the University of Wisconsin adapted a hybrid quadrupole linear ion trap-orbitrap mass spectrometer to use ETD. This method also used a front-end ionization method for the radical anions of 9-anthracenecarboxylic acid via pulsed dual ESI sources.
=== Peptide Folding === Coupling ribosome profiling with ChIP can elucidate how and when newly synthesized proteins are folded. Using the footprints provided by Ribo-Seq, specific ribosomes associated with factors, like chaperones, can be purified. Pausing the ribosome at specific time points, allowing it to translate a polypeptide over time, and exposing the different points to a chaperone and precipitating out using ChIP purifies these samples and can show at which point in time the peptide is being folded.
=== Overdose === Human tolerance to xylazine varies widely, with toxicity and fatality occurring between doses of 40–2,400 mg (0.62–37.04 gr). Non-fatal blood or plasma concentration ranges from 0.03 to 4.6 mg/L. In fatalities, the blood concentration of xylazine ranges from trace to 16 mg/L. It is reported that there is no defined safe or fatal concentration of xylazine because of the significant overlap between the non-fatal and postmortem blood concentrations of xylazine. Hemodialysis has been suggested as a form of treatment, but is usually unfavorable due to the large volume of distribution of xylazine. There are no standardized screenings to determine if an overdose has occurred. Detection of xylazine in humans involves various screening methods, such as urine screenings, thin layer chromatography (TLC), gas chromatography–mass spectrometry (GC-MS) and liquid chromatography–mass spectrometry (LC-MS). As of November 2022, detecting xylazine in a drug sample requires spectrophotometry. As of 1998, the α2-adrenergic receptor antagonist atipamezole was used to reverse the effects of xylazine or the related drug dexmedetomidine in veterinary medicine, but this is not an approved medical treatment for humans, despite Phase I clinical trials in 2005. As of 2001, the effects of xylazine in animals were also reversed by the analeptics 4-aminopyridine, doxapram, and caffeine, which are physiological antagonists to central nervous system depressants. The ways to accurately identify chronic xylazine use are unknown, and the effective treatments, if any, are not standardized.
For services to the community in Rugby, Warwickshire. Margaret Sandra Myers. For services to the community in Sheffield, South Yorkshire. David Mynott. Volunteer, Torfaen Dementia Group. For services to People with Dementia and their Carers. Moez Kass Amali Nathu. Chief Executive, Peterborough Asylum and Refugee Community Association. For services to Refugees and Asylum Seekers in Peterborough. Robert Thomson Nellies. President, Falkland Cricket Club. For services to Cricket and to the community in Fife. Elyn Catherine Neville. For charitable services to Cancer Patients and to Cancer Services in Pembrokeshire. Margaret Alice Newell. Lately Office Manager, Privy Council Office. For Public Service, particularly during the Accession Council. Matthanee Nilavongse. For services to the community in Todmorden, West Yorkshire. William Ellis Nixon. Honorary Secretary, Social Enterprise UK. For services to Young People in the West Midlands. Uzoamaka Louisa Nwokolo. Lately Executive Officer, Department for Transport. For services to Young People. Diana Violet O'Grady. For services to the community in Arreton, Isle of Wight. Samuel Jozef Oldroyd. Chief Executive Officer, JADE Youth and Community. For services to Young People and Families in Rother Valley, South Yorkshire. Clive John Owen. Vice Chair, Aberavon Green Stars Rugby Football Club. For charitable services to Young People and to the community in Aberavon, West Glamorgan. Diane Oxley. For services to Young People and to the community in Thurcroft, South Yorkshire. Tracie Ann Pal.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.
Detection commonly uses liquid chromatography–tandem mass spectrometry. This method can identify the compound in urine or blood at low concentrations.
Typical guidance is −20 °C, dry, and protected from light. Solutions should be aliquoted and limited freeze–thaw cycles should be used.
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.